Sionna Financial Statements From 2010 to 2025
| SION Stock | 43.70 0.33 0.75% |
Check Sionna Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sionna Therapeutics,'s main balance sheet or income statement drivers, such as , as well as many indicators such as . Sionna financial statements analysis is a perfect complement when working with Sionna Therapeutics, Valuation or Volatility modules.
Check out the analysis of Sionna Therapeutics, Correlation against competitors. Sionna Therapeutics, Common Company Return On Equity Analysis
Sionna Therapeutics,'s Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sionna Therapeutics, Return On Equity | -0.28 |
Most of Sionna Therapeutics,'s fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sionna Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Sionna Therapeutics, Common has a Return On Equity of -0.2808. This is 98.83% lower than that of the Biotechnology sector and 99.23% lower than that of the Health Care industry. The return on equity for all United States stocks is 9.42% lower than that of the firm.
Sionna Therapeutics, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sionna Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Sionna Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sionna Therapeutics, competition to find correlations between indicators driving Sionna Therapeutics,'s intrinsic value. More Info.Sionna Therapeutics, Common is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sionna Therapeutics,'s earnings, one of the primary drivers of an investment's value.About Sionna Therapeutics, Financial Statements
Sionna Therapeutics, investors utilize fundamental indicators, such as revenue or net income, to predict how Sionna Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Pair Trading with Sionna Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sionna Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sionna Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Sionna Stock
| 0.84 | VALN | Valneva SE ADR | PairCorr |
| 0.78 | VIVS | VivoSim Labs, Symbol Change | PairCorr |
| 0.75 | RAC | Race Oncology | PairCorr |
| 0.7 | AVH | Avita Medical | PairCorr |
| 0.66 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Sionna Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sionna Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sionna Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sionna Therapeutics, Common to buy it.
The correlation of Sionna Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sionna Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sionna Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sionna Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Sionna Therapeutics, Correlation against competitors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sionna Therapeutics,. If investors know Sionna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sionna Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sionna Therapeutics, is measured differently than its book value, which is the value of Sionna that is recorded on the company's balance sheet. Investors also form their own opinion of Sionna Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Sionna Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sionna Therapeutics,'s market value can be influenced by many factors that don't directly affect Sionna Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sionna Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.